Morgan Stanley is out with its report today on CVS/Caremark (NYSE:
CVS), maintaining Equal-weight.
In its report, Morgan Stanley writes, 'Valuation is temping, but after years of disappointments, CVS needs to prove its PBM operating income performance to the market. We maintain our Equal-weight rating."
Shares of CVS closed Tuesday at $33.80.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
